Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY)

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)
Total
Common Stock [Member]
Advances Under Equity Financing [Member]
Additional Paid-in Capital [Member]
Deficit Accumulated During the Development Stage
Balance at Aug. 09, 2005 $ 0 $ 0 $ 0 $ 0 $ 0
Balance (in shares) at Aug. 09, 2005   0      
Shares issued to founding stockholder 1,500 1,902 0 (402) 0
Shares issued to founding stockholder (in shares)   19,021,786      
Net loss (16,124) 0 0 0 (16,124)
Balance at Dec. 31, 2005 (14,624) 1,902 0 (402) (16,124)
Balance (in shares) at Dec. 31, 2005   19,021,786      
Shares issued in connection with reverse merger transaction 62,500 401 0 62,099 0
Shares issued in connection with reverse merger transaction (in shares)   4,005,177      
Shares issued in private placement, net of offering costs 969,372 355 0 969,017 0
Shares issued in private placement, net of offering costs (in shares)   3,555,220      
Stock-based compensation expense 97,400 0 0 97,400 0
Stock-based compensation expense (in shares)   0      
Net loss (562,084) 0 0 0 (562,084)
Balance at Dec. 31, 2006 552,564 2,658 0 1,128,114 (578,208)
Balance (in shares) at Dec. 31, 2006   26,582,183      
Shares issued in private placement, net of offering costs 531,320 100 0 531,220 0
Shares issued in private placement, net of offering costs (in shares)   999,995      
Stock-based compensation expense 890,694 25 0 890,669 0
Stock-based compensation expense (in shares)   250,000      
Stock-based research and development expense 50,836 0 0 50,836 0
Stock-based research and development expense (in shares)   0      
Net loss (1,648,488) 0 0 0 (1,648,488)
Balance at Dec. 31, 2007 376,926 2,783 0 2,600,839 (2,226,696)
Balance (in shares) at Dec. 31, 2007   27,832,178      
Stock-based compensation expense 357,987 0 0 357,987 0
Stock-based compensation expense (in shares)   0      
Stock-based research and development expense 213,061 10 0 213,051 0
Stock-based research and development expense (in shares)   100,000      
Net loss (1,271,522) 0 0 0 (1,271,522)
Balance at Dec. 31, 2008 (323,548) 2,793 0 3,171,877 (3,498,218)
Balance (in shares) at Dec. 31, 2008   27,932,178      
Shares issued in private placement, net of offering costs 1,097,050 242 0 1,096,808 0
Shares issued in private placement, net of offering costs (in shares)   2,420,000      
Advances under equity financing 1,200,000 0 1,200,000 0 0
Stock-based compensation expense 745,980 15 0 745,965 0
Stock-based compensation expense (in shares)   150,000      
Stock-based research and development expense 132,933 0 0 132,933 0
Stock-based research and development expense (in shares)   0      
Net loss (1,551,333) 0 0 0 (1,551,333)
Balance at Dec. 31, 2009 1,301,082 3,050 1,200,000 5,147,583 (5,049,551)
Balance (in shares) at Dec. 31, 2009   30,502,178      
Shares issued in private placement, net of offering costs 1,087,500 458 (1,200,000) 2,287,042 0
Shares issued in private placement, net of offering costs (in shares)   4,575,000      
Stock-based compensation expense 160,712 0 0 160,712 0
Stock-based compensation expense (in shares)   0      
Stock-based research and development expense 67,222 0 0 67,222 0
Stock-based research and development expense (in shares)   0      
Net loss (880,250) 0 0 0 (880,250)
Balance at Dec. 31, 2010 1,736,266 3,508 0 7,662,559 (5,929,801)
Balance (in shares) at Dec. 31, 2010   35,077,178      
Exercise of stock options 5,000 18 0 4,982 0
Exercise of stock options (in shares)   181,964      
Stock-based compensation expense 204,898 0 0 204,898 0
Stock-based compensation expense (in shares)   0      
Stock-based research and development expense 982 0 0 982 0
Stock-based research and development expense (in shares)   0      
Fair value of warrant extension 199,839 0 0 199,839 0
Net loss (2,067,964) 0 0 0 (2,067,964)
Balance at Dec. 31, 2011 79,021 3,526 0 8,073,260 (7,997,765)
Balance (in shares) at Dec. 31, 2011   35,259,142      
Exercise of stock options 33,333 24 0 33,309 0
Exercise of stock options (in shares)   241,955      
Exercise of stock warrants 2,468,250 608 0 2,467,642 0
Exercise of stock warrants (in shares)   6,082,000      
Stock-based compensation expense 723,554 0 0 723,554 0
Stock-based compensation expense (in shares)   0      
Stock-based research and development expense 293,450 0 0 293,450 0
Stock-based research and development expense (in shares)   0      
Fair value of warrant discount 334,024 0   334,024 0
Fair value of warrant extension 1,139,592 0 0 1,139,592 0
Net loss (3,579,366) 0 0 0 (3,579,366)
Balance at Dec. 31, 2012 1,491,858 4,158 0 13,064,831 (11,577,131)
Balance (in shares) at Dec. 31, 2012   41,583,097      
Stock-based compensation expense 89,567 0 0 89,567 0
Stock-based compensation expense (in shares)   0      
Net loss (702,753) 0 0 0 (702,753)
Balance at Jun. 30, 2013 $ 878,672 $ 4,158 $ 0 $ 13,154,398 $ (12,279,884)
Balance (in shares) at Jun. 30, 2013   41,583,097